spacer
home > pmps > summer 2017 > reducing risks
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Reducing Risks

A pharmaceutical product’s ability to perform its purpose depends on its quality; the user expects the product to be safe, therapeutic and completely fit for function. To meet these criteria, it needs to be intrinsically stable, free of contamination and must reproducibly deliver the therapeutic benefit claimed on the label or in the product information leaflet to the consumer over the period of its shelf life. Such a product is said to deliver its quality through its design, hence the phrase ‘Quality by Design’ (QbD). QbD focuses on integrated product development, commencing at the concept stage (1). These principles have been adopted by the FDA for the discovery, development and manufacturing of drugs and have been developed further for biopharmaceutical products (2,3).

When a product is developed with raw material selection in mind, designing quality and removing formulationassociated risks are key considerations. To this end, using the best materials available is crucial to help manage these aspects of chemistry. Depending on how the drug is to be administered (topically, orally or parenterally), raw material choices and their attributes need to be deliberated, especially where key ‘natural’ materials are to be used. A control strategy needs to be developed for the entire process, including tight supervision on the excipients’ specifications, to ensure consistent quality and product stability over its shelf life.

As such, excipient selection plays a key role in determining the performance of a drug – not only in delivering the efficacy required, but also maintaining this over the product’s lifetime.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Anthony Hubbard, Research and Technology Manager in Health Care at Croda Europe, has worked in product development for over 30 years. He has been involved in the innovation, development and testing of a variety of healthcare, cosmetic and toiletry formulations. In his position at Croda, Anthony’s current focus is on the development of drug delivery systems (parenteral, oral and topical) that enhance the stability and availability of APIs. He has a Bachelor of Science (Hons) and is a fellow of the Royal Society of Chemistry.
spacer
Anthony Hubbard
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New awareness campaign aims to help organisations prepare for GS1


More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>

 
Industry Events

Pharma and Device Packaging and Labeling West Coast 2017

28-29 November 2017, Burlingame, California

Following a very successful launch year, we are thrilled to announce that Pharma and Device Packaging and Labeling will be returning to the West Coast for our 2nd annual event.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement